Literature DB >> 2524387

Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration.

K Ensing1, R A de Zeeuw, G D Nossent, G H Koëter, P J Cornelissen.   

Abstract

Single doses of ipratropium bromide were administered intravenously, orally and by slow inhalation to ten healthy male volunteers. The plasma level after oral administration followed a low but broad plateau persisting for several hours. After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min. The bioavailability was 3.3% (range 0.9-6.1%) on comparing the plasma AUCs following i.v. and 20 mg oral administration. The cumulative renal excretion (0-24 h) after i.v. administration was compared with that after oral administration and inhalation. Following oral administration, the apparent systemic availability was around 2%, and after inhalation it was 6.9%. In comparison with oral placebo administration, only after i.v. administration was there a significant change in heart rate (from 63.7 to 90.2 beats/min). The systolic blood pressure rose from 115.1 to 119.6 mm Hg and the diastolic blood pressure from 68.3 to 78.3 mm Hg.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524387     DOI: 10.1007/bf00609193

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Development of a sensitive radioreceptor assay for oxyphenonium in plasma and urine.

Authors:  K Ensing; F Kluivingh; T K Gerding; R A De Zeeuw
Journal:  J Pharm Pharmacol       Date:  1984-04       Impact factor: 3.765

2.  [Treatment of bradycardia with an atropine ester].

Authors:  F Bender; C Hartmann; B Brisse; B Wichmann
Journal:  Z Kardiol       Date:  1975-04

3.  Radioreceptor assays of ipratropium bromide in plasma and urine.

Authors:  K Ensing; M Pol; R A De Zeeuw
Journal:  J Pharm Biomed Anal       Date:  1988       Impact factor: 3.935

Review 4.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

5.  Secretion of monoquaternary ammonium compounds by guinea pig small intestine in vivo.

Authors:  K Turnheim; F Lauterbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

6.  [Studies on pharmacokinetics and biotransformation of ipratropiumbromide in man (author's transl)].

Authors:  J Adlung; K D Höhle; S Zeren; D Wahl
Journal:  Arzneimittelforschung       Date:  1976

7.  [Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog].

Authors:  H J Förster; I Kramer; K H Pook; D Wahl
Journal:  Arzneimittelforschung       Date:  1976
  7 in total
  7 in total

Review 1.  Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.

Authors:  Bart C Moulton; Allison D Fryer
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

Review 3.  Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.

Authors:  Donald C Bolser
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

Review 4.  Muscarinic receptor antagonists: effects on pulmonary function.

Authors:  Kalmia S Buels; Allison D Fryer
Journal:  Handb Exp Pharmacol       Date:  2012

5.  Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses.

Authors:  K Ensing; R A de Zeeuw; W G in 't Hout; P J Cornelissen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology.

Authors:  Baharudin Abdullah; Amir Hamzah Abdul Latiff; Anura Michelle Manuel; Faizah Mohamed Jamli; Harvinder Singh Dalip Singh; Intan Hakimah Ismail; Jeevanan Jahendran; Jeyasakthy Saniasiaya; Kent Chee Keen Woo; Phaik Choo Khoo; Kuljit Singh; Nurashikin Mohammad; Sakinah Mohamad; Salina Husain; Ralph Mösges
Journal:  J Asthma Allergy       Date:  2022-08-02

7.  Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler.

Authors:  T R MacGregor; R ZuWallack; V Rubano; M A Castles; H Dewberry; M Ghafouri; C C Wood
Journal:  Clin Transl Sci       Date:  2016-03-06       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.